Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.47 |
| ▸ | TUBB | P07437 | 2/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065882 | 0.81 | CYP3A4 (0.46) | CYP3A4CYP2E1CYP2A6TUBB4ATUBB | |
| SCHEMBL3745779 | 0.81 | CYP3A4 (0.46) | CYP3A4CYP2E1CYP2A6TUBB4ATUBB | |
| SCHEMBL24240217 | 0.79 | CYP3A4 (0.50) | CYP3A4CYP2E1CYP2A6TUBB4ATUBB | |
| SCHEMBL27473377 | 0.79 | CYP3A4 (0.44) | CYP3A4CYP2E1CYP2A6TUBB4ATUBB | |
| SCHEMBL14923458 | 0.79 | TUBB4A (0.46) | CYP3A4CYP2E1CYP2A6TUBB4ATUBB | |
| SCHEMBL13466401 | 0.79 | CYP3A4 (0.44) | CYP3A4CYP2E1CYP2A6TUBB4ATUBB | |
| SCHEMBL14761507 | 0.78 | LMNA (0.44) | CYP3A4CYP2E1CYP2A6TUBB4ATUBB | |
| SCHEMBL14761942 | 0.78 | ALDH1A1 (0.64) | CYP3A4CYP2E1CYP2A6TUBB4ATUBB | |
| SCHEMBL1462555 | 0.78 | LMNA (0.44) | CYP3A4CYP2E1CYP2A6TUBB4ATUBB | |
| SCHEMBL1757027 | 0.76 | LMNA (0.54) | CYP3A4CYP2E1CYP2A6ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8293916-B2 | Diazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| CN-1960984-B | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists | HOFFMANN LA ROCHE | 2010-05-12 | — | — | CN | disclosed |
| US-20100048569-A1 | DIAZOLE DERIVATIVES | BUETTELMANN BERND | 2010-02-25 | — | — | US | disclosed |
| EP-1756086-B1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| CN-1960984-A | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | disclosed |
| EP-1756086-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20060030559-A1 | Diazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2005118568-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048569-A1 | DIAZOLE DERIVATIVES | GRM1, GRM2, GRIN2B | CYP3A4 2929/4885CYP2E1 1686/4885CYP2A6 4009/4885 |
| US-20060030559-A1 | Diazole derivatives | GRM1, GRM2, GRIN2B | CYP3A4 2929/4885CYP2E1 1686/4885CYP2A6 4009/4885 |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | CSNK1G1, PRKCE, PHKG1 | CYP3A4 4808/4885CYP2E1 4366/4885CYP2A6 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.